Natural Capsules Limited Shareholders Approve Key Board Changes and Appointments at 32nd AGM

1 min read     Updated on 05 Aug 2025, 11:37 PM
scanx
Reviewed by
Radhika SahaniScanX News Team
whatsapptwittershare
Overview

Natural Capsules' 32nd AGM saw shareholders approve several important resolutions. Mr. Tekkar Yashwanth Prabhu will continue as Non-Executive Independent Director beyond 75 years. Mr. Sathyanarayana Mundra was reappointed as Whole Time Director for three years. Mr. R. Parthasarathy was appointed as Secretarial Auditor for five years. Other approvals included adoption of financial statements, reappointment of Mr. Sushil Kumar Mundra, related party transactions, and commission for Non-Executive Directors. All resolutions passed with overwhelming majority.

15962836

*this image is generated using AI for illustrative purposes only.

Natural Capsules , a leading manufacturer of hard capsule shells, held its 32nd Annual General Meeting (AGM) on August 4, 2025, where shareholders approved several significant resolutions shaping the company's governance and future direction.

Board Continuity and Reappointments

Shareholders gave their nod to the continuation of Mr. Tekkar Yashwanth Prabhu as a Non-Executive Independent Director beyond the age of 75 years until the expiry of his current term. Mr. Prabhu, with over four decades of banking experience, brings valuable expertise to the board, having served in senior positions at Canara Bank, Union Bank of India, and Oriental Bank of Commerce.

The meeting also saw the reappointment of Mr. Sathyanarayana Mundra as Whole Time Director for a three-year term, effective September 20, 2025, along with a revision in his remuneration. Mr. Mundra, responsible for quality control of products, will continue to play a crucial role in the company's operations.

New Appointments

In a move to strengthen its corporate governance, the company appointed Mr. R. Parthasarathy as Secretarial Auditor for a period of five consecutive years, from the financial year 2025-26 to 2029-30. Mr. Parthasarathy, a practicing Company Secretary with 38 years of experience in company law matters, brings extensive expertise to this role.

Other Key Resolutions

The AGM also addressed several other important matters:

  1. Adoption of audited financial statements for the year ended March 31, 2025.
  2. Reappointment of Mr. Sushil Kumar Mundra as a director, who was retiring by rotation.
  3. Approval of related party transactions with the subsidiary, Natural Biogenex Private Limited.
  4. Approval for the payment of commission to Non-Executive Directors.

Voting Results

All resolutions put forth at the AGM were passed with overwhelming majority. The e-voting results showed 100% votes in favor for most resolutions, indicating strong shareholder support for the company's decisions.

Management's Perspective

While specific comments from the management were not provided, the approval of these resolutions suggests a focus on maintaining experienced leadership, enhancing corporate governance, and preparing for future growth.

Natural Capsules, known for pioneering the manufacturing of vegetarian capsules in India, continues to evolve its governance structure to support its position as a key player in the pharmaceutical industry. These board-level changes and appointments are likely aimed at steering the company through its next phase of growth and expansion.

Historical Stock Returns for Natural Capsules

1 Day5 Days1 Month6 Months1 Year5 Years
-0.75%+25.61%+38.47%+43.41%+9.02%+9.02%
Natural Capsules
View in Depthredirect
like20
dislike

Natural Capsules Reports Mixed Q1 Results: Standalone Profit Amid Consolidated Loss

2 min read     Updated on 04 Aug 2025, 07:55 PM
scanx
Reviewed by
Naman SharmaScanX News Team
whatsapptwittershare
Overview

Natural Capsules reported mixed Q1 financial results. Standalone performance showed growth with Rs 44.24 crore revenue and Rs 2.52 crore net profit. Consolidated results reflected challenges, with Rs 45.20 crore revenue but Rs 5.58 crore net loss. The Capsules segment remained profitable, while the new API segment incurred significant losses. The subsidiary, Natural Biogenex Private Limited, started operations recently and is yet to reach full revenue potential.

15863105

*this image is generated using AI for illustrative purposes only.

Natural Capsules , a leading pharmaceutical company, has reported mixed financial results for the first quarter. The company's standalone performance showed growth, while its consolidated results reflected challenges in its API segment.

Standalone Performance

On a standalone basis, Natural Capsules demonstrated resilience with a revenue from operations of Rs 44.24 crore. The company reported a net profit of Rs 2.52 crore, translating to an earnings per share (EPS) of Rs 2.44.

Consolidated Results

The consolidated financial picture, however, painted a different story. While the consolidated revenue stood at Rs 45.20 crore, the company reported a net loss of Rs 5.58 crore, resulting in a negative EPS of Rs 5.40.

Segment-wise Performance

The company's financial results revealed a stark contrast between its two main segments:

  1. Capsules Segment: This segment remained profitable, contributing Rs 44.24 crore to the revenue and generating a profit of Rs 4.84 crore before tax and interest.

  2. API Segment: The newly operational API segment reported a revenue of Rs 96.02 lakh but incurred a significant loss of Rs 6.99 crore before tax and interest.

Subsidiary Operations

Natural Biogenex Private Limited, a subsidiary of Natural Capsules, commenced commercial operations on March 31, 2025. The company noted that the subsidiary is still in the process of achieving its full revenue potential, which contributed to the consolidated loss.

Management Commentary

Mr. Sunil L Mundra, Managing Director of Natural Capsules Limited, stated, "While our standalone performance remains strong, we are navigating challenges in our API segment. The loss in this segment is primarily due to our subsidiary, Natural Biogenex Private Limited, which is in its early stages of commercial operations. We are confident that as the subsidiary ramps up its operations, it will positively contribute to our consolidated results in the coming quarters."

Corporate Governance

The company's board has designated Mr. Sunil L Mundra as the Managing Director for determining the materiality of events, and Ms. Pranjal Deshmukh as the Company Secretary for disclosure submissions, in compliance with SEBI regulations.

Outlook

Despite the consolidated loss, Natural Capsules remains optimistic about its future prospects. The management expects the API segment to improve its performance as operations stabilize and scale up in the coming quarters.

Investors and stakeholders will be closely watching the company's performance in subsequent quarters, particularly the progress of its API segment and the subsidiary's contribution to the overall financial health of the company.

Natural Capsules continues to focus on its core competencies while navigating the challenges in its new ventures. The company's ability to turn around its consolidated performance will be crucial for its growth trajectory in the pharmaceutical sector.

Historical Stock Returns for Natural Capsules

1 Day5 Days1 Month6 Months1 Year5 Years
-0.75%+25.61%+38.47%+43.41%+9.02%+9.02%
Natural Capsules
View in Depthredirect
like17
dislike
Explore Other Articles
272.05
-2.05
(-0.75%)